The Harry T. Mangurian, Jr. Foundation Commits $4 Million to Blood Cancer Research

The Harry T. Mangurian, Jr. Foundation Strengthens Commitment to Blood Cancer Research

The philanthropic landscape continues to evolve with impactful partnerships that can lead to breakthroughs in medical research. Recently, Blood Cancer United® (formerly recognized as The Leukemia & Lymphoma Society) announced a significant new commitment of $4 million from The Harry T. Mangurian, Jr. Foundation. This fresh investment elevates the foundation's total contributions to over $25 million in support of vital initiatives aimed at combating blood cancer over the span of 15 years.

A Long-standing Partnership

Since its inception, The Harry T. Mangurian, Jr. Foundation has been a cornerstone supporter of Blood Cancer United, significantly influencing the field of blood cancer research, clinical trials, and pediatric initiatives. The organization has utilized these funds to foster innovative projects such as Light The Night, which aims to support community fundraising and raise awareness about blood cancers.

Dr. E. Anders Kolb, President and CEO of Blood Cancer United, emphasized the importance of sustained financial support in the pursuit of scientific advancements. In his words, ‘Scientific progress depends on bold, long-term investments.’ This sentiment underscores the necessity of continued support to transition groundbreaking ideas from initial discovery to successful patient outcomes.

Investment in Innovation

The newly allocated $4 million will be utilized in multiple key areas crucial to enhancing blood cancer treatment and research:
1. AI-Powered Research Innovation: The funds aim to expedite clinical trials and enhance discovery efficiency through innovative programs such as the Beat AML initiative.
2. Pediatric Cancer Research: Focused on advancing treatments for younger patients, the investment will bolster the PedAL Master Clinical Trial, making promising therapies available more rapidly.
3. Development of Early-Career Scientists: The Career Development Program funded by the foundation is designed to sustain promising research through nurturing the next generation of scientists in the field.
4. Emerging Therapies: The Therapy Acceleration Program® (TAP) will further support innovative biotech firms dedicated to developing new treatments tailored for blood cancer patients.

Continuing Impact

Throughout its collaboration with Blood Cancer United, The Harry T. Mangurian, Jr. Foundation has significantly advanced various research trajectories and changed clinical approaches in blood cancer treatment. Their contributions have facilitated innovative clinical trials and expanded research opportunities for pediatric patients, thereby impacting countless lives within this population.

Notably, the Beat AML initiative has successfully screened over 1,850 patients, with more than 640 actively enrolled in associated studies. On the pediatric front, the Dare to Dream Project has made monumental strides, injecting over $41 million into pediatric research since its inception in 2019, showcasing the continuous and invaluable contributions from this foundation.

As expressed by Stephen Mehallis, President of The Harry T. Mangurian, Jr. Foundation, ‘We are pleased to provide this continuing support for Blood Cancer United’s ongoing battle against blood cancers.’

Conclusion

With the foundation’s latest commitment, Blood Cancer United is positioned to enhance its already significant impact in the fight against blood cancers. As both organizations look forward to the future, it is clear that their alliance is vital in driving impactful change and paving the way for discoveries that could change countless lives affected by blood cancers. For more information about Blood Cancer United’s initiatives, visit their website at www.BloodCancerUnited.org.